

# (19) United States

## (12) Patent Application Publication (10) Pub. No.: US 2021/0325392 A1 Buranda et al.

Oct. 21, 2021 (43) **Pub. Date:** 

(54) ACTIVATED GTPASE-BASED ASSAYS AND KITS FOR THE DIAGNOSIS OF SEPSIS AND OTHER INFECTIONS

(71) Applicant: UNM RAINFOREST

INNOVATIONS, Albuquerque, NM

(US)

(72) Inventors: Tione Buranda, Albuquerque, NM

(US); Jacob Ongudi Agola, Albuquerque, NM (US); Soumik BasuRay, Dallas, TX (US); Scarlett Swanson, Albuquerque, NM (US); Angela Wandinger-Ness, Albuquerque, NM (US); Peter C. Simons,

Albuquerque, NM (US); Virginie Bondu, Albuquerque, NM (US)

(21) Appl. No.: 17/182,859

(22) Filed: Feb. 23, 2021

### Related U.S. Application Data

(62) Division of application No. 16/270,306, filed on Feb. 7, 2019, now Pat. No. 10,962,541, which is a division of application No. 14/626,536, filed on Feb. 19, 2015, now Pat. No. 10,261,084.

(60) Provisional application No. 61/941,604, filed on Feb. 19, 2014.

#### **Publication Classification**

(51) Int. Cl.

G01N 33/573 (2006.01)G01N 33/86 (2006.01)

(52) U.S. Cl.

CPC ...... G01N 33/573 (2013.01); G01N 33/86 (2013.01); G01N 2800/224 (2013.01); G01N 2800/26 (2013.01); G01N 2333/914 (2013.01)

#### (57)ABSTRACT

In one embodiment, the invention provides a method of diagnosing sepsis or a virus-related infection (often a viral hemorrhagic fever infection) in a subject by detecting and measuring the level of a set of sepsis and virus infectionassociated-GTPase biomarkers in a sample obtained from the subject using multiplexed flow cytometry. Related kits are also provided. In a preferred embodiment, the invention provides point of care diagnostic methods for determining an early stage sepsis or the severity of a virus infection, especially in a hospital or other setting.